California is home to our corporate headquarters, as well as AMPAC Fine Chemicals largest manufacturing facility and analytical services laboratory. Established in 1942, the manufacturing facility encompasses over 240 acres in Rancho Cordova (near Sacramento). It has 310 m³ (81,930 US gal) of capacity supporting cGMP manufacturing for APIs and Intermediates at all scales. This site is also our Center of Excellence for batch and SMB chromatography.
Our contract analytical services at AMPAC Analytical specialize in method development, validation, release testing, and stability studies for cGMP Intermediates, APIs and a variety of Drug Product formulations.
Our cGMP manufacturing facility in La Porte, Texas (near Houston) has over 91 m³ (24,100 US gal) of capacity for small- and large-scale cGMP manufacturing. Known for our expertise in energetic and hazardous chemistry, we safely handle reactions involving phosgene, cyanide, azide, nitration, POCl3, hydrogenation, alkylation, hydride reduction, Grignard, and chlorination.
Our cGMP API manufacturing facility in Petersburg, Virginia (near Richmond) encompasses over 150 acres and 188 m³ (49,550 US gal) of capacity. Our multiple production lines include reactors ranging from 0.75 m³ (200 US gal) to 7.57 m³ (2,000 US gal) for all scales of production.
Our facility in Swords, Dublin, Ireland holds almost 60 years of experience in small and large-scale API and Intermediate manufacturing. This facility has 97 m³ (25,616 US gal) capacity and is specifically designed for API validation and commercial production. This facility also serves as our Center of Excellence for Material Science.
Located near Paris, France, Yposkesi is a leading CDMO for companies developing cell and gene therapies. The company has one of the largest AAV (Adeno-Associated Virus) and lentiviral vector production capacities in Europe. Its current 5,000 m² facility operates multiple manufacturing suites for bulk drug substance (up to 1000L) and Fill & Finish. Yposkesi is doubling its footprint with a second bioproduction site, providing capacity for early clinical to commercially available biologics.
We operate a highly automated pilot and commercial scale API manufacturing facility in Sejong, Korea. This facility currently has 189 m³ (50,000 US gal) of capacity with an expansion in progress adding 104 m³ (27,474 US gal) of additional capacity. Built in 2017, we utilize cutting-edge technology to perform both batch and continuous processes.
Daejeon, Korea is home to our Process R&D Center. This facility also manufactures clinical material and supports commercial API and Intermediate production. Our Daejeon facility provides 87 m³ (22,910 US gal) capacity and is our Center of Excellence for Continuous Processing.